

1 **Membrane-Localized Mutations Predict the** 2 **Efficacy of Cancer Immunotherapy**

3
4 Priscilla S. Briquez¹⁺, Sylvie Hauert^{1 *}, Zoe Goldberger^{1,2 *}, Trevin Kurtanich¹,
5 Aaron T. Alpar¹, Grégoire Repond¹, Yue Wang¹, Suzana Gomes¹, Prabha
6 Siddarth³, Melody A. Swartz^{1,4,5,6}, Jeffrey A. Hubbell^{1,5,6+}

7
8 * These authors contributed equally to this work

9 † Correspondence: jhubbell@uchicago.edu, pbriquez@uchicago.edu

10 11 **Affiliations:**

12 ¹ Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA

13 ² Department of Bioengineering, McGill University, Montreal, QC, Canada

14 ³ Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, CA, USA

15 ⁴ Ben May Department of Cancer Research, University of Chicago, Chicago, IL, USA

16 ⁵ Committee on Immunology, University of Chicago, Chicago, IL, USA

17 ⁶ Committee on Cancer Biology, University of Chicago, Chicago, IL, USA

18

19 **SUPPLEMENTARY INFORMATION**

20

21 **Supplementary Data 1:** Subcellular locations of proteins associated with *Homo*
22 *Sapiens* genes.

23 **Supplementary Data 2:** Proportion of mutations at specific location for ICI-treated
24 cohort from Samstein *et al.*⁷

25 **Supplementary Data 3:** Proportion of mutations at specific location for the non-ICI-
26 treated cohort from Samstein *et al.*⁷

27 **Supplementary Data 4:** Proportion of mutations at specific location for the NSCLC
28 patients cohort from Hellman *et al.*⁸


29 **Supplementary Data 5:** Proportion of mutations at specific location for the
30 melanoma patients cohort from Hugo *et al.*⁹

31 **Supplementary Data 6:** HR of survival per mutated genes and per cancer type for
32 the ICI and non-ICI treated patients cohort from Samstein *et al.*⁷

33

34

35



Supplementary Fig. 1. Characterization of OVA-expressing B16-F10 melanoma cell lines and tumors. **a**, Design of the different OVA-expressing B16-F10 cell lines, expressing membrane OVA (mOVA) or soluble OVA. **b**, OVA expression in the modified B16 cell lines in culture *in vitro*, assessed by qPCR ($N \geq 6$, mean \pm SD, ANOVA with Sidak's post-test). **c**, OVA expression in the modified B16 tumors *in vivo*, assessed by qPCR ($N \geq 4$, mean \pm SD, ANOVA with Sidak's post-test). **d**, Cell-surface staining of OVA quantified by flow cytometry via the mean fluorescence intensity. **e**, Detection of cell plasma membrane-bound OVA on the different OVA-expressing B16 cell lines assessed by microscopy (red: anti-OVA; scale bar = 50 μm). **f**, Western blot analysis for OVA detection in the extracellular vesicles (EV) produced *in vitro* by B16mOVA^{HI} or B16-OVA^{HI} cell lines or in the non-EV fraction (black = positive detection of OVA). **g**, Survival of mice injected with the different OVA-expressing cell lines, associated to the tumor growth curves of Fig. 1a ($N \geq 8$, log-rank tests with Holm-Bonferroni p-values adjustment). **h**, Tumor growth of B16mOVA^{HI} in Act-mOVA mice as compared to growth in wild-type (WT) mice ($N \geq 3$, mean \pm SEM, Kruskal-Wallis with Dunn's post-test at day 10).

36

37

38

39

40

41

42

43

44

45

46

47

48

49


50

51

52

53

54




55

56

57 **Supplementary Fig. 2. Gating strategy for the characterization of T and NK cells.** Multi-
 58 colored flow cytometry was used to analyze the subsets of T and NK cells in the tumors at
 59 day 10 post-injection. Subset of immune cells were defined using the following markers:
 60 NK cells (FSC^{LO}, SSC^{LO}, CD45⁺, NK1.1⁺, CD3ε⁻), NK T cells (FSC^{LO}, SSC^{LO}, CD45⁺, CD3ε⁺,
 61 NK1.1⁺), CD8⁺ T cells (FSC^{LO}, SSC^{LO}, CD45⁺, NK1.1⁻, CD3ε⁺, CD8⁺), CD4⁺ T cells (FSC^{LO},
 62 SSC^{LO}, CD45⁺, NK1.1⁻, CD3ε⁺, CD8⁺), effector T cells (same markers than T cells with
 63 CD44⁺, CD62L⁻), effector memory T cells (same markers than T cells with CD44⁺, CD62L⁺).
 64 regulatory T cells (same as CD4⁺ T cells with CD25⁺, FoxP3⁺).

65

66



67

68

69 **Supplementary Fig. 3. Gating strategy for the characterization of B cells and myeloid**

70 **cell subsets.** Multi-colored flow cytometry was used to analyze the subsets of B cells and

71 myeloid cells in the tumors at day 10 post-injection. Subset of immune cells were defined

72 using the following markers: Macrophages (CD45⁺, F4/80⁺, CD11b⁺), Granylocytic myeloid-

73 derived suppressor cells (MDSC) (CD45⁺, F4/80⁻, CD3ε⁻, Ly6G⁺, Ly6C^{MID/HI}), Monocytic

74 MDSC (CD45⁺, F4/80⁻, CD3ε⁻, Ly6G⁻, Ly6C^{HI}), B cells (CD45⁺, F4/80⁻, CD3ε⁻, Ly6G⁻,


75 Ly6C^{LO/MID}, CD19⁺, B220⁺), dendritic cells (DCs) (CD45⁺, F4/80⁻, CD3ε⁻, Ly6G⁻, Ly6C^{LO/MID},

76 CD11c⁺, MHCII⁺), CD11b⁺ DCs (same than DCs with CD11b⁺), CD103⁺ DCs (same than DCs

77 with CD11b⁻, B220⁻, CD103⁺).


78

79



80

81 **Supplementary Fig. 4. Comparison of B16mOVA and B16-OVA melanoma tumor**
 82 **immunogenicity and responsiveness to cancer immunotherapy in mice. a-e,** Flow
 83 cytometry analysis of immune cells infiltrated in tumors 10 days post-injection (N≥4, mean ±
 84 SD, ANOVA with Tukey's post-test and Brown-Forsythe correction when needed). **a,** Number
 85 of CD45⁺ immune cells and CD8⁺ T cells per mg of tumor. **b,** CD8⁺ and **c,** CD4⁺ effector and
 86 effector memory T cells subsets in the different tumors. **d,** Proportion of PD-1 expressing
 87 CD8⁺ and CD4⁺ T cells. **e,** Proportion of NK T cells, B cells, dendritic cells, macrophages and
 88 myeloid-derived suppressor cells relative to the total CD45⁺ immune cell populations. **f,** Titers
 89 (log₁₀) of the anti-OVA measured per IgG subtype in the plasma of tumor-bearing mice at day
 90 10, which corresponds Fig. 1d. (N≥4, mean ± SD, Kruskal-Wallis with Dunn's post-test per
 91 IgG subtype). **g,** Tumor growth and associated survival of OVA-expressing tumor-bearing
 92 mice treated with 100 μg of anti-PD-L1 and 100 μg of anti-CTLA-4 injected intraperitoneally
 93 when the tumor volume reached 20-50 mm³ (grey thresholds) (N≥3, mean ± SEM, log-rank
 94 tests). **h,** Survival of mice re-challenged with B16-F10 WT tumor cells, associated to the
 95 tumor growth curves presented in Fig. 1i (N≥8, mean ± SEM, log-rank test).



96

97

98

99

100

101

102

103

104

105

106

107

108


109

110

111

112

Supplementary Data Fig. 5. Analysis of tumor mutated genes' subcellular localizations and their subsequent impact on patient survival. **a**, Number of tumor mutated genes associated with each subcellular location among the 469 genes sequenced by MSK-IMPACT method. **b**, Proportion of tumor mutated genes per subcellular location in patients treated with immunotherapy in the pan-cancer group, and corresponding percentile cutoff values used for the analysis in Fig. 2. **c**, Survival of ICI-treated patients harboring high (Top 50% or 10%) or low (Bottom 50% or 10%) mTMB (log-rank tests). **d**, Increase in risk of death as a function of mTMB in ICI-treated patients in the pan-cancer group. Values are calculated as $100 \cdot (\text{HR} - 1) \pm 95\% \text{ CI}$ with HR the hazard ratio for survival of patients that have less than the depicted proportion as compared to those that have more. As an example, ICI-treated patients that had less than Q1=23% of mutated genes at the membrane had a 50% increased risk of death as compared to those that have more than 23% membrane mutated genes (log-rank tests, red values = p-value ≤ 0.05 , grey values = not significant). **e**, Survival of ICI-treated patients with high (Top 25%) mTMB and sTMB (log-rank test).



113

114

115

116

117

118


119

120

121

122

Supplementary Fig. 6. Distributions of patients by cancer types and according to their mTMB. **a**, Distribution of the ICI-treated patients per cancer type included in the pan-cancer analysis. **b**, Differences in patient distribution per cancer type for the groups with high (Top 25%) or low (Bottom 25%) mTMB, as compared to the distribution of the entire ICI-treated cohort as in panel a. **c**, Values of the HRs, 95% confidence intervals, p-value of the log-rank tests and number of patients used in Fig. 3b, for the universal cutoff and the 25% top vs. bottom strategies.



123

124 **Supplementary Fig. 7. Response to immunotherapy based on the proportion of**

125 **mutated genes at specific subcellular localizations.** Patients (N=75) with non-small cell

126 lung cancer were treated with anti-PD-1 + anti-CTLA-4 in the cohort from Hellman *et al.*⁸, and

127 patients (N=38) with advanced melanoma cancer were treated with anti-PD-1 in the cohort

128 from Hugo *et al.*⁹. In both studies, tumor mutated genes were sequenced by the WES

129 method. **a**, Number of tumor mutated genes detected across all patients in the Hellman *et al.*

130 and Hugo *et al.* studies, respectively, and their associated subcellular locations.

131 **b**, Comparison of the mTMB found in ICI-treated patient cohorts from the studies by Samstein


132 *et al.*⁷, Hellman *et al.*⁸ and Hugo *et al.*⁹ **c**, Proportion of mutated genes per subcellular location

133 in patients that responded or not to immunotherapy in the Hellman *et al.* cohort (Mann-

134 Whitney test). **d**, Survival of patients with high (Top 25% and 50%) or low (Bottom 25% and

135 50%) mTMB in the Hellman *et al.*⁸ cohort (log-rank test). **e**, Same as in panel c, but with the

136 patient cohort from Hugo *et al.*⁹ **f**, Proportion of responders or non-responders to anti-PD-1
137 among patients that have high (Top 25%) or low (Bottom 25%) mTMB in the Hugo *et al.*⁹
138 cohort (Fisher's exact test). **g**, Same as in panel d, but with the patient cohort from Hugo *et*
139 *al.*⁹. **h**, Proportion of mutated genes at the cell plasma membrane or in other specific
140 membrane-containing cell organelles in responders and non-responders to immunotherapy
141 from the Hugo *et al.*⁹ **i**, Survival of the patients with high (Top 10%) or low (Bottom 10%)
142 proportion of mutated genes expressing proteins at the tumor cell plasma membrane for the
143 pan-cancer groups from the cohort from Samstein *et al.*⁷
144
145



146

147

148

149

150

151

152

153

154

155

156

157

158

159

Supplementary Fig. 8. Potential use of mTMB and specific membrane-associated mutated genes as predictive clinical biomarkers for extended survival upon ICI. Data analyzed from Samstein *et al.*⁷ ICI-treated or non-ICI-treated cohorts. **a**, Survival of patients bearing at least one mutated genes among the cancer-specific list of genes highlighted in blue in Fig. 5a, as compared to patients with no mutated genes among the list. **b**, Survival curves of ICI and non-ICI treated patients bearing *RNF43* mutations in colorectal cancer. **c**, Survival curves of ICI and non-ICI treated patients bearing *NOTCH1* mutations in NSCLC. **d**, Comparison of survival of patients carrying *RET* mutations in NSCLC treated with ICI or with a standard-of-care cabozantinib (data from Gautschi *et al.*²⁵). **e**, Survival curves of patients from the pan-cancer group in function of their TMB level (in mut/Mbp). The higher the TMB the longer the survival (log-rank test). **f**, Correlation between mTMB and total TMB. No correlation was observed between these two parameters (Spearman correlation).